Literature DB >> 8431925

Chemotherapy of carcinoma of the stomach.

M Findlay1, D Cunningham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8431925     DOI： 10.1016/0305-7372(93)90025-m

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  11 in total

1.  Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies.

Authors:  G S Patel; K Jain; R Kumar; A H Strickland; L Pellegrini; J Slavotinek; M Eaton; W McLeay; T Price; M Ly; S Ullah; B Koczwara; G Kichenadasse; C S Karapetis
Journal:  Support Care Cancer       Date:  2013-09-05       Impact factor: 3.603

2.  Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen.

Authors:  André M Murad; Nils G Skare; Jéferson Vinholes; Sérgio Lago; Ricardo Pecego
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

3.  Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy.

Authors:  Jian-Wei Lu; Chang-Ming Gao; Jian-Zhong Wu; Hai-Xia Cao; Kazuo Tajima; Ji-Feng Feng
Journal:  J Hum Genet       Date:  2006-01-20       Impact factor: 3.172

4.  Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.

Authors:  Henning Schulze-Bergkamen; Ivan Zuna; Andreas Teufel; Wolfgang Stremmel; Jochen Rudi
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

5.  Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.

Authors:  M González-Barón; J Feliu; E Espinosa; C García-Girón; I Chacón; P Garrido; A Colmenarejo; A Ordóñez; P Zamora
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.

Authors:  A A Melcher; D Mort; T S Maughan
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

7.  A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.

Authors:  C Kollmannsberger; D Quietzsch; C Haag; T Lingenfelser; M Schroeder; J T Hartmann; W Baronius; V Hempel; M Clemens; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

Review 8.  Continuous 5-fluorouracil in the treatment of breast cancer.

Authors:  D A Cameron; H Gabra; R C Leonard
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

9.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Authors:  S Pyrhönen; T Kuitunen; P Nyandoto; M Kouri
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

10.  Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Authors:  Y Chao; K H Yeh; C J Chang; L T Chen; T Y Chao; M F Wu; C S Chang; J Y Chang; C Y Chung; W Y Kao; R K Hsieh; A L Cheng
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.